IntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays. The company’s partner, RedHill Biopharma (NSDQ:RDHL), has decided to end its co-development and commercialization relationship with IntelGenx, the news site reported. “We were expecting RedHill’s decision because in recent […]